Furthermore, using a phospho - tyrosine [Y] 474 (in - house generated) and a phospho - serine [S] 176 (Cell Signaling, Inc., Danvers, MA) RIPK2 antibodies, we confirmed that active RIPK2 is recognized by
these antibodies upon activation with MDP treatment in 293HEK fibroblast and HCT116 colon cancer epithelial cells (Fig. 3E, left panel) and detection of constitutively active RIPK2 in the colon cancer cell line SW480 (Fig. 3E, right panel).
«We wanted to utilize platelets» intrinsic tendencies to accumulate at wounds and to interact with circulating tumor cells, for targeted delivery of immune checkpoint inhibitors» said Gu, «Interestingly, we found the
antibody can be promoted to release from activated platelets in the surgical site, due to generation of small platelet - derived microparticles
upon the platelet
activation.